卵巢癌治疗后动态随访血清CA125预测复发和预后的价值

The Value of Examining Serum CA125 Level Dynamically after Therapy for the Recurrence and Prognosis of Ovarian Carcinoma

目的 评价卵巢癌治疗后动态检测血清 CA12 5对临床复发和预后预测的价值。方法 采用微粒子酶免分析法随访测定了 36例进展期卵巢癌患者治疗后的血清 CA12 5。结果 36例中 ,治疗后血清 CA12 5略有下降 4例 ,但CA12 5值仍 >6 5 KU/ L ,治疗后 CA12 5反而升高者 3例 ,显著降低者 2 9例 ,其中 14例完全阴转。预测复发的阳性预测值 10 0 % ,阴性预测值为 83.3%。对生存情况随访结果显示 ,治疗后 CA12 5无明显下降或反常升高的 7例患者 ,4例于 1a内死亡 ,3例 2 a内死亡 ;2 9例 CA12 5明显下降者 ,其 1a生存率 86 % ,2 a生存率 76 % ,与前组相比后者有明显差别 (χ2=6 3.182 6 ,P<0 .0 0 1)。结论 治疗后动态随访血清 CA12 5水平不仅可以预测复发、转移 。

Objective To evaluate the value of examining serum CA125 level dynamically after therapy for the recurrence and prognosis of ovarian carcinoma.Methods Microparticle enzyme immunoassay technique was used to examine serum CA125 levels of 36 patients with aggressive ovarian carcinoma after therapy.Results 4 cases showed slightly decreased CA125,but still more than 65 KU/L;3 showed striking higher CA125; 29 showed remarkably decreased CA125,in which 14 showed negative. Positive and negative predictive values for recurrence were 100% and 83.3%, respectively.It was found after follow up that for all the 7 patients whose CA125 levels hadn′t decreased remarkably, 4 died in one year and the other 3 in 2 years,while for all the 29 patients whose CA125 levels decreased remarkably,survival rates of 1 year or 2 years were 86% and 76%,respectively,showing significantdifference when compared with the former(χ 2=63.1826,P<0.001).Conclusion To examine the serum CA125 level dynamically after therapy could be useful to predict not only recurrence but pregnosis of aggressive ovarian carcinoma.